In August 2012, Bristol-Myers Squibb acquired Amylin Pharmaceuticals, a biopharmaceutical company focused on the research, development and commercialization of a franchise of GLP-1 agonists for the treatment of type 2 diabetes.

2012

In November 2011, Bristol-Myers Squibb and ASLAN Pharmaceuticals announced an innovative partnership to license and develop an investigational oncology compound.

2011

In October 2011, Bristol-Myers Squibb and Gilead Sciences, announced licensing agreement for development and commercialization of new fixed-dose combination pill for people living with HIV.

In September 2011, Bristol-Myers Squibb and Ambrx, Inc., announced a collaboration to research, develop and commercialize novel biologics programs in diabetes and heart failure.

In September 2011, Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd., entered into a strategic agreement to expand Bristol-Myers Squibb’s territorial rights to an investigational cancer immunotherapy, an anti-PD-1 antibody, and for the co-development and co-commercialization of Orencia® in Japan.

In September 2011, Bristol-Myers Squibb acquired Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

In July 2011, Bristol-Myers Squibb and Innate Pharma announced a global agreement for the development and commercialization of an investigational immuno-oncology biologic.

In December 2010, Bristol-Myers Squibb acquired the worldwide rights from Oncolys BioPharma Inc. to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor in Phase II development for HIV.

2010

In October 2010, Bristol-Myers Squibb acquired ZymoGenetics, securing an existing product, RECOTHROM® (recombinant), as well as pipeline assets in hepatitis C, cancer and other therapeutic areas.

Bristol-Myers Squibb and Allergan, Inc. announced a global agreement for the development and commercialization of an oral medication for the treatment of neuropathic pain.

August 2012

Alder Biopharmaceuticals Inc.
Bristol-Myers Squibb entered into a global collaboration with Alder Biopharmaceuticals Inc. of Bothell, Washington, to develop and commercialize a novel investigational biologic for the treatment of rheumatoid arthritis.

2009

Medarex
Worldwide co-development and co-promotion agreement covering ipilimumab for the treatment of metastatic melanoma established in 2004. Bristol-Myers Squibb acquired Medarex in August 2009.

We entered into a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Limited for the development and commercialization of NTC-801, a selective inhibitor of the acetylcholine-activated potassium ion channel (IKACh) for the maintenance of normal sinus rhythm in patients with atrial fibrillation.

Bristol-Myers Squibb entered into a global collaboration with ZmyoGenetics of Seattle, Washington to develop and commercialize PEG-Interferon lambda, a new treatment for hepatitis C.

Bristol-Myers Squibb entered into a development/commercialization agreement with KAI Pharmaceuticals for a cardiovascular disease therapy.

2008

Bristol-Myers Squibb purchased Kosan Biosciences, a cancer therapeutics company based in California, for approximately $190 million. This acquisition enhanced the company’s pipeline with compounds in two important classes of anticancer agents.

Bristol-Myers Squibb entered into an agreement with PDL BioPharma of California to develop and globally commercialize a therapy for multiple myeloma.

Pfizer
Worldwide co-development and co-promotion agreement for the Bristol-Myers Squibb - discovered apixaban, a Factor Xa inhibitor for thrombosis.

2007

Adnexus
Discovery/development agreement for adnectins against multiple oncology targets. Bristol-Myers Squibb acquired Adnexus in 2007, following the collaboration’s earlier success.

AstraZeneca
Co-development and co-promotion agreement for ONGLYZA™ (saxagliptin), approved by the FDA for the treatment of type 2 diabetes in adults, and dapagliflozin, an investigational compound for the treatment of type 2 diabetes.

Albany
Agreement to identify triple re-uptake inhibitors for clinical development for depression and other CNS diseases; led to additional research collaboration screening Albany’s natural products library against multiple targets looking for novel hit compounds

Ambit
Agreement to screen selected lead compounds against targets in Ambit’s KinomeScan panel of kinases; relationship extended and expanded twice to include all lead compounds and all compounds in BMS’s kinase-specific compound library.

2004

Gilead Sciences
Co-development and co-promotion collaboration for ATRIPLA® (efavirenz/emtricitabine/tenofovir disoproxil fumarate), a fixed-dose, co-formulated combination product for treatment of HIV.

Lexicon
Target discovery collaboration to look for novel neuroscience compounds identified in Lexicon’s gene knock-out Genome5000 project; and development collaboration for compounds that modulate the targets for use against neuroscience diseases.

2003

Exelixis
Collaboration to identify novel oncology targets; led to subsequent collaborations for developing clinical compounds against LXR target for cardiovascular and metabolic diseases and providing IND compounds in oncology. Most recent collaboration involves an agreement to develop and commercialize two novel therapies: one for medullary thyroid cancer and the other for treatment of patients with advanced solid tumor malignancies.

2001

Please click on the product links to see the full prescribing information including boxed WARNINGS for ATRIPLA®

Click here for trademark information on Bristol-Myers Squibb products.

Otsuka
Co-development and co-marketing agreement for ABILIFY® (aripiprazole).

1999

sanofi-aventis
Co-development and co-promotion/co-marketing agreement for the antiplatelent agent PLAVIX® (clopidogrel bisulfate tablets) and the angiotensin-II receptor antagonist for hypertension AVAPRO® (irbesartan).

1997

Lipha
Bristol-Myers Squibb acquires U.S. rights for GLUCOPHAGE® (metformin hydrochloride), which becomes the leading oral treatment for Type 2 diabetes in the U.S. and a top-seller worldwide.

1994

National Cancer Institute
Cooperative research and development agreement for the anti-cancer drug TAXOL® (paclitaxel). TAXOL becomes one of the most widely used cancer treatments in the world.

1991

Please click on the product links to see the full prescribing information including boxed WARNINGS for ABILIFY®, PLAVIX®, GLUCOPHAGE®, TAXOL® AVAPRO® regarding use in pregnancy. As soon as pregnancy is detected, discontinue use of AVAPRO®.

Click here for trademark information on Bristol-Myers Squibb products.

Yale University
Bristol-Myers Squibb acquires rights to ZERIT® (stavudine) for treatment of HIV.

1987

Sankyo
Co-marketing agreement for cholesterol-lowering agent PRAVACHOL® (pravastatin sodium).

1985

Please click on the product links to see the full prescribing information including boxed WARNINGS for ZERIT®, PRAVACHOL®.

Click here for trademark information on Bristol-Myers Squibb products.